The Use of PrevenaTM on Clean Closed Sternal Midline Incisions in Subjects at High Risk for Surgical Site Occurrences.

Not Applicable

Terminated

Interventions: Device: Conventional sterile wound dressings
Device: Prevena™ Incision Management System

Brief Summary: The purpose of this study is to compare the use of Prevena™ Incision Management System (IMS) versus standard wound care for the incision in subjects undergoing a sternal midline incision (sternotomy). The subjects targetted for the study are at high risk for surgical complications (like infections) around the environment of the incision.

The study is conducted in The Netherlands, Germany and Austria.

Detailed Description: The Prevena™ IMS is intended to manage the environment of closed surgically incision and surrounding intact skin for patients with an increased risk for developing post-operative complications such as infection.The purpose of this study is to compare the use of Prevena™ Incision Management System (IMS) versus standard wound care for the incision in subjects undergoing a sternal midline incision (sternotomy). The subjects targetted for the study are at high risk for surgical complications (like infections) around the environment of the incision.

The Prevena™ IMS is a small portable device, which consists of a mild vacuum unit that delivers negative pressure and a dressing that is intended for use over closed incisions after surgery. It is used for a minimum of 4 days up to a maximum of 7 days. This system is commercially available and has a CE mark, which means that it is approved for the use on the European market. It is intended to be applied immediately post sternotomy surgery on a closed clean incision.

The results of this study could contribute to a better and faster healing of the incision.

The study is conducted in The Netherlands, Germany and Austria.

Recruitment & Eligibility

Inclusion Criteria

Is male or female and 18 years of age or older
Is scheduled for elective cardiac surgery for which a median sternotomy is needed (including coronary artery bypass grafting (CABG), valvular repair or replacement with or without CABG). Elective surgery is defined as planned surgery a minimum of 24 hours before the procedure.
Is capable of providing informed consent, which must be obtained prior to any study-related procedures
Is willing and able to adhere to the study visit schedule and other protocol requirements.

Exclusion Criteria

Is pregnant
The use of Prevena post surgery is contra indicated per investigator's discretion
Has a systemic infection at the time of surgery: systemic infection is diagnosed on the basis of clinical signs of sepsis with or without a positive culture of an organism from the bloodstream
Has a remote body site infection at the time of surgery (including dental, urinary or skin soft tissue infections)
Is known to have a current nasal swab positive for methicillin-resistant staphylococcus aureus (MRSA)
Has a known allergy or hypersensitivity to silver, or drape materials that contain acrylic adhesives
Has a requirement for competing wound therapy and procedures.
Any concomitant therapies (including other NPWT treatment) or procedures deviating from the clinical standard incision treatment or with investigational device at the location of the sternotomy (e.g. use of NPWT at other location of the body is allowed)
Any other therapies or procedures that, in the opinion of the treating physician, would affect or influence postoperative wound stability or healing
Is simultaneously participating in another interventional trial
Requires use of liquid skin adhesives or glues during skin closure
Is known to be serology positive for hepatitis B, hepatitis C or HIV

Arm && Interventions

Group	Intervention	Description
Conventional sterile wound dressings	Conventional sterile wound dressings	Subjects will receive standard conventional wound therapy (SCWT) placed in the operating room, defined as using conventional sterile wound dressings (gauze).
Prevena™ Incision Management System	Prevena™ Incision Management System	Subjects will receive sternal wound treatment in the operating room using Prevena™ Incision Management System according to the intended use

Primary Outcome Measures

Name	Time	Method
Surgical Site Infection (SSI) Rate Within 34 Days Postoperatively, Defined as Superficial, Deep, and Organ/Space Infections as Per CDC Guidelines.	30 ± 4 days	The SSI rate (in %) was calculated for each treatment arm as follows: SSI rate = \[Number of Subjects who experienced SSI\] / \[Number of Subjects Analyzed\] \* 100 Subjects included in the numerator for the SSI rate computation must have experienced an SSI post-surgery up to Day 30 (± 4 days). If a subject has the same SSI event on multiple occasions or experiences several events of other SSIs, the subject will be counted only once in the numerator for the first event

Secondary Outcome Measures

Name	Time	Method

Locations (13): Catharina Ziekenhuis Eindhoven
🇳🇱
Eindhoven, Noord-Brabant, Netherlands
Medizinische Universitat Graz
🇦🇹
Graz, Austria
Medizinische Universitaet Wien, Universitätsklinik für Chirurgie
🇦🇹
Vienna, Austria
Deutsches Herzzentrum Berlin
🇩🇪
Berlin, Germany
Charité Berlin
🇩🇪
Berlin, Germany
Universitätsklinikum Erlangen
🇩🇪
Erlangen, Germany
Westfälische Wilhelms-Universität Münster
🇩🇪
Münster, Germany
Klinikum Nürnberg
🇩🇪
Nurnberg, Germany
University Medical Center Groningen
🇳🇱
Groningen, Netherlands
Isala Klinieken
🇳🇱
Zwolle, Overijssel, Netherlands
Thoraxcentrum Research BV, Erasmus University Medical Center Rotterdam
🇳🇱
Rotterdam, Zuid-Holland, Netherlands
Stichting St. Antonius ziekenhuis
🇳🇱
Nieuwegein, Utrecht, Netherlands
Clinical Research Center Salzburg GmbH
🇦🇹
Salzburg, Austria